Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine

Bibliography

• Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-56
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation Patient Registry. 2008 Annual Data Report to the Center Directors. Bethesda, Maryland: Cystic Fibrosis Foundation; 2007
   Google Scholar
• Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-61
   PubMed Web of Science ®Google Scholar
• Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19:10-5
   PubMed Web of Science ®Google Scholar
• Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-14
   Google Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-51
   PubMed Web of Science ®Google Scholar
• Fogarty A, Hubbard R, Britton J. International comparison of median age at death from cystic fibrosis. Chest 2000;117:1656-60
   Google Scholar
• Cystic Fibrosis Trust. UK CF Registry Annual Data Report 2008. Available from: http://www.cftrust.org.uk/aboutcf/publications/cfregistryreports/UK_CF_Registry-Annual_ Data_Report_2008.pdf [Last accessed 27 January 2010]
   Google Scholar
• Rosenfeld M, Emerson J, Williams-Warren J, Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-65
   PubMed Web of Science ®Google Scholar
• Amadori A, Antonelli A, Balteri I, Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis. Respir Med 2009;103:407-13
   PubMed Web of Science ®Google Scholar
• Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008;7:523-30
   PubMed Web of Science ®Google Scholar
• Foweraker J. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br Med Bull 2009;89:93-110
   PubMed Web of Science ®Google Scholar
• Tunney MM, Field TR, Moriarty TF, Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008;177:995-1001
   PubMed Web of Science ®Google Scholar
• Courtney JM, Bradley J, Mccaughan J, Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007;42:525-32
   PubMed Web of Science ®Google Scholar
• Bittar F, Richet H, Dubus JC, Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008;3:e2908
   PubMed Web of Science ®Google Scholar
• Lee TW, Brownlee KG, Denton M, Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004;37:104-10
   PubMed Web of Science ®Google Scholar
• Taccetti G, Campana S, Neri AS, Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis. J Chemother 2008;20:166-9
   PubMed Web of Science ®Google Scholar
• Ho SA, Lee TW, Denton M, Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J Cyst Fibros 2009;8:43-6
   PubMed Web of Science ®Google Scholar
• Douglas TA, Brennan S, Gard S, Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009;33:305-11
   PubMed Web of Science ®Google Scholar
• Flume PA, O'sullivan BP, Robinson KA, Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69
   PubMed Web of Science ®Google Scholar
• Heijermann H, Westerman E, Conway S, Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8:295-315
   Google Scholar
• Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3 – Management. Thorax 2008;63:180-4
   PubMed Web of Science ®Google Scholar
• Flume PA, Mogayzel PJ Jr, Robinson KA, Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MW, Quan JM, Cystic fibrosis inhaled tobramycin study group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Eng J Med 1999;340:23-30
   PubMed Web of Science ®Google Scholar
• US prescribing information, TOBI®, tobramycin inhalation solution, USP. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/tobi.pdf [Last accessed 27 January 2010]
   Google Scholar
• Hodson ME, Gallagher CG. New clinical evidence from the European tobramycin trial in cystic fibrosis. J Cyst Fibros 2002;1(Suppl 2):199-202
   Google Scholar
• Summary of Product Characteristics (SPC), TOBI® 300°mg/5°ml Nebuliser Solution Website of UK licensed medicines. Available from: http://emc.medicines.org.uk/ [Last accessed 27 January 2010]
   Google Scholar
• Summary of Product Characteristics (SPC), Promixin® 1 MIU Powder for Nebuliser Solution. Website of UK licensed medicines. Available from: http://emc.medicines.org.uk/ [Last accessed 27 January 2010]
   Google Scholar
• Coulthard K. Maximizing the efficacy and safety of colistimethate therapy [abstract S19.2]. Pediatr Pulmonol 2008;43(Suppl 31):193-5
   Google Scholar
• Li J, Nation RL, Turnidge JD, Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet 2006;6:589-601
   Google Scholar
• Kuhn RJ. Formulation of aerosolized therapeutics. Chest 2001;120:94S-8S
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of Product Characteristics (SPC), Cayston® 75 mg powder and solvent for nebuliser solution. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/cayston/emea-combined-h996en.pdf [Last accessed 27 January 2010]
   Google Scholar
• Heath Canada. Product Monograph: Cayston® (Aztreonam for Inhalation Solution 75 mg aztreonam/vial antibiotic. Available from: http://www.hc-sc.gc.ca/index-eng.php [Last accessed 27 January 2010]
   Google Scholar
• FDA. Prescribing Information: Cayston® (aztreonam for inhalation solution). Available from: http://www.cayston.com/media/CAYSTON_prescribe_info.pdf [Last accessed 26 February 2010]
   Google Scholar
• Prescribing information: AZACTAM® (aztreonam) for injection, USP. Available from: http://www.elan.com/ [Last accessed 27 January 2010]
   Google Scholar
• In: Parfitt K, editor, Aztreonam. Martindale: the complete drug reference. 32nd edition. Pharmaceutical Press, London; 1999. p. 156-7
   Google Scholar
• Dietzsch HJ, Gottschalk B, Heyne K, Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 1975;55:96-100
   PubMedGoogle Scholar
• Georgopapadakou NH, Smith SA, Sykes RB. Mode of action of aztreonam. Antimicrob Agents Chemother 1982;21:950-6
   Google Scholar
• Johnson DH, Cunha BA. Aztreonam. Med Clin North Am 1995;79:733-43
   PubMed Web of Science ®Google Scholar
• Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17:479-501
   PubMed Web of Science ®Google Scholar
• Sykes RB, Bonner DP. Aztreonam: the first monobactam. Am J Med 1985;78:2-10
   PubMedGoogle Scholar
• Brogden RN, Heel RC. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986;31:96-130
   Web of Science ®Google Scholar
• Adkinson NF Jr. Immunogenicity and cross-allergenicity of aztreonam. Am J Med 1990;88(3C):12S-5S, discussion 38S-42S
   Google Scholar
• Geller DE. The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2008;43(Suppl 9):5-17
   Google Scholar
• Gibson RL, Retsch-Bogart GZ, Oermann C, Microbiology, safety and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41:656-65
   PubMed Web of Science ®Google Scholar
• Retsch-Bogart GZ, Quittner AL, Gibson RL, Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009;135:1223-32
   PubMed Web of Science ®Google Scholar
• McCoy KS, Quittner AL, Oermann CM, Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-8
   PubMed Web of Science ®Google Scholar
• Hofmann T, Otto K, Kirihara J, Safety and tolerability study of aztreonam for inhalation (AI) in healthy volunteers [abstract 195]. Pediatr Pulmonol 2003;36(Suppl 25):251
   Google Scholar
• Retsch-Bogart GZ, Burns JL, Otto KL, A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008;43:47-58
   PubMed Web of Science ®Google Scholar
• Oermann CM, Retsch-Bogart GZ, McCoy KS, Effect of multiple courses of aztreonam for inhalation solution (AZLI) on disease-related endpoints and safety in patients with CF: final analysis of 18-month data [abstract 241]. Pediatr Pulmonol 2009;44(Suppl 32):296
   Google Scholar
• Oermann CS, McCoy KS, Retsch-Bogart GZ, Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens [abstract 353]. Pediatr Pulmonol 2009;44(Suppl 32):335-6
   Google Scholar
• Oermann CS, McCoy KS, Retsch-Bogart GZ, Antibiotic susceptibility in Pseudomonas aeruginosa (PA) isolates following repeated exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis [abstract 278]. Pediatr Pulmonol 2009;44(Suppl 32):309
   Google Scholar
• Oermann CM, Retsch-Bogart GZ, Quittner AL, An 18-month study, AIR-CF3, of the safety and improvement in pulmonary function and respiratory symptoms with repeated courses of aztreonam for inhalation solution in patients with cystic fibrosis and airway Pseudomonas aeruginosa. Pediatr Pulmonol 2010; in press
   Google Scholar
• Quittner AL, Sweeny S, Watrous M, Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol 2000;25:403-14
   PubMed Web of Science ®Google Scholar
• Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatric Psychol 2003;28:535-46
   PubMedGoogle Scholar
• Quittner AL, Buu A, Messer MA, Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005;128:2347-54
   PubMed Web of Science ®Google Scholar
• Abbott J. Health-related quality of life measurement in cystic fibrosis: advances and limitations. Chron Respir Dis 2009;6:31-41
   PubMedGoogle Scholar
• US FDA Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM193282.pdf [Last accessed 27 January 2010]
   Google Scholar
• Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol 1992;45:1341-45
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7
   PubMed Web of Science ®Google Scholar
• Testa MA. Interpretation of quality-of-life outcomes: issues that affect magnitude and meaning. Med Care 2000;38:166-74
   Google Scholar
• Guyatt GH. Making sense of quality-of-life data. Med Care 2000;38:175-9
   Google Scholar
• Terwee CB, Dekker FW, Wiersinga WM, On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Qual Life Res 2003;12:349-62
   PubMed Web of Science ®Google Scholar
• Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 2007;4:378-86
   Google Scholar
• Quittner AL, Modi A, Wainwright C, Determination of the minimal clinically important difference (MCID) scores for the Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Symptom scale in two populations of patients with CF and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-18
   PubMed Web of Science ®Google Scholar
• Montgomery AB, S Lewis M, K Higuchi M, Hospitalization risk of current standard of care (SOC) vs. aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) [abstract]. Am J Respir Crit Care Med 2009;179:A1188
   Google Scholar
• Braff M, Retsch-Bogart G, McCoy K, Effect of 28-day aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis (CF) respiratory pathogens [abstract]. Am J Respir Crit Care Med 2009;179:A5944
   Google Scholar
• McCoy KS, Retsch-Bogart G, Gibson R, Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis [abstract 418]. Pediatr Pulmonol 2008:43(Suppl 31):351
   Google Scholar
• Elborn JS, Hodson M, Bertram C. Implementation of European standards of care for cystic fibrosis – control and treatment of infection. J Cyst Fibros 2009;8:211-17
   Google Scholar
• Burns JL, Emerson J, McNamara S, Antibiotic resistance in cystic fibrosis sputum isolates [abstract 373]. Pediatr Pulmonol 2008;43(Suppl 31):334
   Google Scholar
• Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs 2009;69:1903-10
   PubMed Web of Science ®Google Scholar